What are the main effects and mechanisms of action of Ensartinib?

Ensartinib is a new generation oral small molecule tyrosine kinase inhibitor (TKI), mainly used to treat ALK (anaplastic lymphoma kinase)-positive non-small cell lung cancer (NSCLC) patients. ALK rearrangement is a driver gene mutation that can lead to continued abnormal proliferation of lung cancer cells. Ensartinib achieves anti-tumor purposes by highly selectively inhibiting ALK kinase activity, thereby effectively blocking the growth signaling pathways of tumor cells.

A notable feature of ensartinib is its resistance to multiple ALK resistance mutations (such as L1196M, G1269A, etc.) have strong inhibitory capabilities, which makes it an important treatment option for patients who are resistant to crizotinib (crizotinib). In addition, it can penetrate the blood-brain barrier and exert a therapeutic effect on central nervous system (CNS) metastatic lesions, which is particularly important in patients with advanced lung cancer, because brain metastasis is a common and difficult clinical problem in ALK-positive NSCLC.

Clinical studies have shown that ensartinib has better progression-free survival (PFSPFSPFSPFSPFSin treatment-naïve patients who have not been treated with ALK inhibitors). span>) advantages, while having good objective response rate (ORR) and disease control rate (DCR). For patients who have received other ALK inhibitors but developed resistance, ensartinib can also exert significant anti-tumor activity and is one of the important drugs in second-line or even third-line treatment.

In general, ensartinib, as a new generation of ALK targeted drug, has the advantages of strong selectivity, wide coverage of drug-resistant mutations, and significant control effect on brain metastasis. it isALK Positive non-small cell lung cancer gradually occupies a more important position in the treatment, providing patients with more long-term and precise treatment options. With the deepening of research, its application potential in other ALK-driven tumors is gradually being explored.

Reference materials:https://www.drugs.com/